1. Diagnostic Accuracy and Prognostic Value of Core Biopsy in the Management of Breast Cancer: A Series of 542 Patients
- Author
-
Aurelia Noske, Sylvia Müller, Achim Schneider, and Christiane Richter-Ehrenstein
- Subjects
Oncology ,medicine.medical_specialty ,Receptor, ErbB-2 ,Biopsy ,Breast Neoplasms ,Diagnostic accuracy ,HER2/neu ,Pathology and Forensic Medicine ,Breast cancer ,Predictive Value of Tests ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Breast ,skin and connective tissue diseases ,Neoplasm Staging ,biology ,business.industry ,Carcinoma, Ductal, Breast ,Reproducibility of Results ,Prognosis ,medicine.disease ,Carcinoma, Intraductal, Noninfiltrating ,Receptors, Estrogen ,biology.protein ,Female ,Surgery ,Radiology ,Anatomy ,Receptors, Progesterone ,business ,Core biopsy - Abstract
Purpose. Core biopsy is considered to be a highly accurate method for gaining preoperative diagnosis of breast cancer. The purpose of this study is to compare the results of core biopsy with those of the surgical excision specimen. Experimental design. A total of 567 core biopsies with subsequent surgical excision were performed. Results. In 488 patients, invasive breast cancer was diagnosed in the preoperative biopsy and in 486 patients (99.6%) the surgical specimen showed identical results. In 160 of the 502 patients (32%) with invasive breast cancer, DCIS was found in the surgical specimen but was not diagnosed in the biopsy. Estrogen and progesterone receptor demonstrated a high rate of agreement, Her2/neu analysis showed a complete concordance in 54% of patients. Conclusions. Core biopsies allow diagnosis of invasive breast cancer with high accuracy. Levels of agreement have to be improved for the detection of DCIS and Her2/neu status.
- Published
- 2008
- Full Text
- View/download PDF